The prevalence of the apolipoprotein E (APOE) ε4 allele is ~50-60% in Alzheimer's disease (AD) dementia, compared to ~15-20% in the general population. However, since earlier studies included subjects without biomarker confirmation of amyloid  (A) pathology, the true prevalence of APOE ε4 in AD is unclear.
Introduction
Alzheimer's disease (AD) is the most common type of dementia, and a major cause of morbidity and mortality worldwide. 1 Pathological metabolism and accumulation of -amyloid (A) peptides is thought to be an initiating event in AD, leading to downstream spread of tau pathology, synaptic loss, atrophy and cognitive decline. [2] [3] [4] Several risk factors may affect or accelerate the development of AD, including age, life-style, and genetic factors. [5] [6] [7] The strongest genetic risk factor associated with sporadic AD is the apolipoprotein E (APOE) gene. 8, 9 APOE encodes for apolipoprotein E, which is a major lipid transporting protein in the brain. In humans, the gene exists in three allele variants called 2, 3, and 4. Compared to APOE 3/3 (the most common genotype), APOE 4 heterozygosity increases the risk for developing clinical AD by about 3-4 times, and APOE 4 homozygosity by about [10] [11] [12] [13] [14] [15] times. 8, 10 The overall prevalence of APOE 4 positivity has been reported to be approximately 15-20% in the normal population 10, 11 and 50-60% in patients with AD dementia 8, 9, 12 . These numbers, however, vary widely and may depend on different characteristics of the study population, including geographical location. 12 Additionally, most previous studies included clinically defined AD patients, without neuropathological confirmation and/or supportive pathophysiological AD biomarkers. Studies applying cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers have revealed that a substantial number of patients with a clinical diagnosis of AD dementia have no evidence of A-pathology [13] [14] [15] [16] , which makes underlying AD pathology highly unlikely. Furthermore, this mismatch between the clinical diagnosis and A biomarkers seems especially prevalent in APOE 4 non-carriers, as illustrated by a clinical trial in which 36% of APOE 4-negative patients with a diagnosis of "AD dementia" in fact lacked A pathology as determined by PET. 17 Another critical point of previous studies on the prevalence of APOE 4 is the focus on the dementia stage of AD. AD is believed to follow a long trajectory in which A pathology is present and clinical symptoms gradually develop before the threshold for dementia is reached. [18] [19] [20] Few studies have investigated APOE 4 positivity in prodromal AD 21 , i.e., mild cognitive impairment (MCI) due to AD, but prevalence rates around 25-55% have been reported. Similarly, not many studies included the proportion of APOE 4 carriers among people with preclinical AD, i.e. presence of A pathology without clinical symptoms. [22] [23] [24] Earlier studies emphasize the importance of the matter; among 1345 study participants (including patients with AD-type dementia, MCI, other dementias, as well as cognitively normal individuals), APOE 4 was found to be more strongly associated with biomarker We aimed to investigate the prevalence of APOE 4 positivity across the clinical spectrum of AD in a large sample of A biomarker-positive individuals, including cognitively normal controls (CN), MCI, and AD dementia. We also tested whether the prevalence of APOE 4 positivity varied by age, sex and geographical location. For comparison, we included a group of A-negative participants.
METHODS

Participants
For this study, we used data from the Amyloid Study Group, which is a worldwide collaborative project on A PET and CSF biomarkers in conjunction with several demographic, clinical and genetic variables. 5, 25 From all contributing sites, we received individual participant-level data on 9,480 individuals (3,611 CN, 3,972 MCI, 1,359 probable AD dementia and 538 non-AD dementia). In addition, we supplemented these data with the Swedish BIOFINDER study 26 (including 292 CN and 217 MCI). Since we aimed to investigate the prevalence of APOE 4 across the clinical spectrum of AD, we applied the following selection procedure for this study: i) we excluded patients with a non-AD dementia, ii) among CN, MCI or AD dementia participants, we selected A-positive (A+) individuals as determined by PET and/or CSF and their A-negative (A-) counterparts for comparison, and iii) we excluded individuals who lacked information on APOE 4 status.
Normal cognition was defined as normal scores on cognitive tests, the absence of cognitive complaints for which medical help was sought, or both. 5 Some of the CN participants had subjective cognitive impairment (SCD, n=533 [102 A+, 431 A-]), defined as presence of a cognitive complaint with presentation at a health care facility but normal cognition on neuropsychological tests 27 . In this paper, SCD subjects were combined with the other CN. 20 MCI and probable AD dementia were defined according to established diagnostic criteria. 18, 19, 28 A-"AD dementia" cases most likely do not have AD as the underlying cause of their cognitive impairment, although it should be noted that A biomarkers are not perfect and could misclassify subjects, especially when biomarker signals are close to the cutoffs. 29, 30 .Characteristics of participants from each contributing site can be found in Supplemental Table 1 .
PET/CSF procedures
Individual PET scans were dichotomized (A+ or A-) using quantitative thresholds or visual reads according to the method used at the study site. 5, 25 CSF biomarkers were dichotomized as negative (normal) or positive (abnormal) using study-specific cutoffs. 5 Detailed PET/CSF procedures for each site are presented in Supplemental Table 1 .
APOE genotyping
By design, all participants in this study had data on APOE 4 status. For 2,955/3,114 (95.5%) CN and 3,054/3,335 (91.6%) MCI subjects we had the specific genotypes (e.g. 3/4, in addition to APOE 4 status), which allowed breakdown into APOE 4 non-carriers, heterozygotes and homozygotes. Specific genotypes were not available for AD dementia patients.
Age, sex, education and geographical location
Information on age was available for all participants. There were missing data for sex (130/7,419, 1.8%) and years of education (1,137/7,419, 15 .3%). We used a previously published classification system for geographical location 12 included in a multicenter study that covered multiple geographical locations.
Statistical analyses
Baseline differences between diagnostic groups were assessed using analysis of variance (with post hoc Bonferroni correction) and X 2 tests, where appropriate. The prevalence of APOE ε4 positivity was obtained by calculating the percentage of APOE ε4-positive individuals of the total number of participants in each diagnostic group. Generalized estimating equations (GEE) were used to estimate the effects of age, sex, education and geographical location on the prevalence of APOE ε4 positivity. GEE was the method of choice for the study as it allows analysis of binary-correlated data, such that participant-level data from all cohorts can be modeled while simultaneously accounting for participants within studies. A logit link function for binary outcome with an exchangeable correlation structure was assumed to account for within-study correlation. Analyses were conducted using the total study population, unless specified otherwise. Age was entered as a continuous measure centered at the mean. We tested 2-way and 3-way interactions between variables, and these terms were retained in the model if they appeared significant by the Wald statistical test. The GEE derived unstandardized βcoefficients and standard errors (SE) of the main effect were reported. Significance level was set at a 2-sided P value less than .05. SPSS software (IBM, version 23.0) was used for statistics.
RESULTS
Participants
Demographic and clinical information for each diagnostic group is provided in Table 1 . We included a total of 7,419 subjects, including 970 with a clinical diagnosis of AD dementia (853 A+, 117 A-), 3,335 with MCI (1,180 A+, 1,525 A-) and 3,114 CN subjects (788 A+, 2,326 A-). Demographic differences between the diagnostic groups included less males in the CN group compared to the other groups (p<0.05) and shorter education in the MCI group compared to the other groups (p<0.001). Furthermore, in the dementia group A status was only determined using PET, and in the MCI group the proportion of subjects with CSF data (78%) was greater than that in the CN group (64.9%). In A+ individuals only, comparisons within diagnostic groups between APOE ε4-positive and -negative groups showed that the mean age was lower in APOE ε4-positive than in APOE ε4-negative CN and MCI patients (p<0.01) (Supplemental Table 2 ).
Prevalence of APOE ε4 positivity
In A+ subjects, the prevalence of APOE ε4 positivity was 50.9% in CN, 63.5% in MCI and 66.1% in AD dementia ( Table 1 ). The prevalence of APOE ε4 positivity was higher in A+ MCI and A+ AD dementia than in A+ CN (p<0.001), but there was no difference between A+ MCI and A+ AD dementia (p=0. 19) . For comparison, the APOE ε4 prevalence in Asubjects was 24.5% in CN, 27.9% in MCI and 24.8% in AD dementia, which was significantly lower than in A+ subjects (all p<0.001).
Prevalence of APOE ε4 positivity by age, sex and education
The prevalence of APOE ε4 positivity was lower at older age in A+ CN (β for change in prevalence per year ± standard error: -0.02±0.01, p<0.05, Figure 1 ) and A+ MCI (β=-0.03±0.01, p<0.01). For example, at age 50, the prevalence of APOE ε4 positivity was 61% in A+ CN and 75% in A+ MCI, compared to 42% and 47% at age 90, respectively (Supplemental Figure 1 ). There was no age effect in AD dementia (β=0.01±0.01, p=0.66).
There was also no effect of age in AD dementia when excluding patients (n=91) with a known atypical presentation (e.g. posterior cortical atrophy or logopenic variant primary progressive aphasia), which are typically associated with lower prevalence of APOE ε4 (β=0.00±0.01, p=0.99, Supplemental Figure 2 ). In A-subjects, the prevalence of APOE ε4 also decreased with age in CN (β=-0.03±0.01, p<0.001; difference with A+: p=0.62) and MCI (β=-0.03±0.01, p<0.001; difference with A-: p=0.82), but not in AD dementia (β=-0.01±0.02, p=0.55; difference with A+: p=0.19)). All effects described above were similar when adjusting for sex and education.
In A+ subjects, sex and education had no direct effects on APOE ε4 positivity, either across or within diagnostic groups (all p>0.05). Furthermore, in A+ subjects there was an interaction between age and sex (p<0.05), whereby prevalence decreased with age for women but not for men. Examining the three-way interaction with diagnosis revealed that the interaction between age and sex was present in MCI (p<0.01), and at trend level in AD dementia (p=0.053), but not in CN subjects (p=0.26). In A-MCI subjects, there was a trend towards greater APOE ε4 positivity in women (β: 0.19±0.10, p=0.06). There were no effects within or across diagnostic groups for education and no interaction effects (all p>0.05). See Supplemental Table 3 for an overview of all main and interaction effects.
Prevalence of specific APOE genotypes in CN and MCI
Next, we stratified CN (n=2,955 [751 A+, 2,204 A-]) and MCI (n=3,054 [1,638 A+, 1,416 A-]) subjects with APOE genotype information available into groups of APOE ε4 non-carriers, APOE ε4 heterozygotes and APOE ε4 homozygotes, and divided them into quartiles according to age. Both in CN and MCI the proportion of APOE ε4 heterozygotes and APOE ε4 homozygotes decreased with advancing age (Figure 2 ).
Prevalence of APOE ε4 positivity by geographical location
Finally, we assessed the effect of geographical location on prevalence of APOE ε4 positivity.
Within A+ subjects, we found that the prevalence of APOE ε4 positivity across diagnostic groups was higher in Northern Europe compared with all other geographical locations except Australia (all p<0.001, Bonferroni-corrected; Figure 3A ). In addition, the prevalence of APOE ε4 positivity was lower in Southern Europe compared to North America, Central Europe (p<0.05, uncorrected) and Australia (p<0.001, Bonferroni-corrected), and higher in Australia than in Asia (p<0.05, uncorrected). Within A-subjects, the prevalence of APOE ε4 positivity was higher in Northern Europe (p<0.001, Bonferroni-corrected) and Central Europe (p<0.05, uncorrected) compared to all other geographical locations ( Figure 3B ). These findings were similar when assessing each diagnostic group separately (Supplemental Figure 3 and Supplemental Table 4 ).
Discussion
We found that the prevalence of APOE 4 positivity was 51% in preclinical AD (A+ CN) 64% in prodromal AD (A+ MCI) and 66 % in A+ AD dementia. Among A-subjects the prevalence of APOE 4 positivity was 25% in CN, 28% in MCI and 25% in AD dementia.
Our estimates of APOE 4 prevalence in A biomarker-verified AD-type dementia are higher than reported in previous studies that defined AD A main finding of this study was that the prevalence of APOE 4 decreased with age in preclinical and prodromal AD. There are several possible explanations. First, as APOE 4
accelerates the onset of amyloid aggregation by approximately 15 years 5, 22 , the prevalence of 4 carriers in A+ subjects will be higher at younger age ranges. Second, supposedly due to the increased risk for cardiovascular diseases in 4 carriers, APOE 4 has been linked to increased mortality rates. [31] [32] [33] This fits our finding that APOE 4 carriership also decreased with age in A-CN and MCI subjects, although the reduction of APOE 4 in A-subjects can also be caused by individuals transitioning from A-to A+ with advancing age. Finally, the additive effects of APOE 4 and A may have resulted in a greater conversion from the CN and MCI groups to AD dementia. 34 Remarkably, the prevalence of APOE 4 did not change with age in AD-type dementia. We tested whether this lack of an age effect was caused by the inclusion of atypical variants of AD dementia 35 , but also after excluding these patients there were no age-effects on the prevalence of APOE 4 carriership. The pathogenesis of early-onset AD is complex, since this group includes a mix of APOE 4 carriers who develop the disease at younger age and of APOE 4 non-carriers with rapidly progressive AD. 36, 37 This may confound relationships between APOE 4 and age especially in young patients with AD-type dementia. Furthermore, it has been shown that the mortality effect of APOE 4 is less pronounced at older age, which may explain the lack of an age effect even in late-onset AD patients. 38 Another main finding was the lower prevalence of APOE 4 in both A+ and A-CN subjects compared to the MCI and dementia stages. This may be explained by a selection bias, as the majority of the MCI and AD dementia subjects visited at a memory clinic, while most CN subjects were recruited as research volunteers. Also, APOE 4+ MCI patients may be more likely to seek medical help as a consequence of a positive family history for dementia.
Another possible reason is that APOE 4 may accelerate the transition from preclinical to clinical AD. For example, APOE 4 may have A-independent effects on brain structure and function [39] [40] [41] [42] [43] , which may act synergistically with A pathology to shorten the time between start of A deposition and cognitive decline. Another possibility is that APOE 4 may cause a more rapid accumulation of A, and thereby shorten the time until A pathology reaches a critical threshold that may be required to trigger downstream effects, including spread of tau, atrophy, and cognitive decline.
We also found geographical differences in APOE 4 prevalence, with higher prevalence in AD patients from Northern Europe, Central Europe, and Australia, and lower prevalence in patients from Southern Europe and Asia. This is consistent with previous epidemiological studies in clinically diagnosed AD dementia patients and MCI. 12, 44 The novelty of this study is that we confirm these geographical differences in A biomarker-defined AD, and throughout the continuum from preclinical to prodromal and dementia stages. Overall, the geographical trends are consistent with lower prevalence of APOE 4 in general populations in Southern Europe and Asia compared to Northern Europe. [44] [45] [46] The different geographical prevalence of APOE 4 may be important both for recruitment of participants in clinical trials, and for the use of APOE 4 in algorithms to predict A positivity. 47 Strengths of this study include the large number of A-positive subjects across the spectrum from preclinical to prodromal and dementia stages of AD. Limitations include that relatively few participants came from Central Europe, Southern Europe, Asia and Australia, and there were no participants from Africa and South America. There were no data on race of the participants, which may confound the results since race has been related to both APOE 4 and AD. 46, 48 Finally, A positivity was determined using different modalities (i.e. PET or CSF) and methods (e.g. visual read versus quantitative threshold for PET and different assays for CSF). In previous studies, however, we found only little evidence for heterogeneity related to modality and methodology in the Amyloid Study Group data. 5, 25 With about 2/3 of prodromal AD and AD dementia patients being APOE 4 carriers, our results emphasize the importance of APOE 4 for the development of AD. This may be useful both for development of disease-modifying treatments, which may be focused on attenuating the detrimental effects of APOE 4, and for understanding the molecular pathogenesis of AD.
However, APOE 4 does not explain all cases of AD, since ~1/3 of A-biomarker-positive AD patients were APOE 4-negative. This is important, since there may be molecular differences between APOE 4-negative and -positive individuals with A pathology, including differences in metabolism of A and amyloid precursor protein (APP). 49 Furthermore, the finding that the prevalence of APOE 4 decreases in CN and MCI subjects has potential implications for clinical trials in pre-dementia populations, as screening based on APOE status to enrich for A positivity may be less effective with advancing age.
CONCLUSIONS
We have quantified the prevalence of APOE 4 in A biomarker-defined preclinical AD, prodromal AD and AD dementia. The results emphasize the prominent role of APOE 4 in AD, but also points to disease heterogeneity, since APOE 4 positivity is markedly less common in elderly subjects in pre-dementia stages of AD and in people from specific geographical locations, including Southern Europe and Asia. Further studies on phenotypic differences between APOE 4-negative and APOE 4-positive AD patients may be important to understanding different pathways that may lead to AD, and ultimately to tailor diseasemodifying treatments to specific patient subgroups. Data are presented as mean±SD unless indicated otherwise. Differences between diagnostics groups (assessed separately for Aβ-positive and Aβnegative groups) were assessed using ANOVA (age, education, MMSE) and X 2 tests (sex, modality and APOE ε4 status) with post hoc Bonferroni tests. 
SUPPLEMENTAL FIGURE LEGENDS:
Figure S1. Prevalence of APOE ε4 positivity by age, diagnosis and Aβ status 95% confidence intervals of slopes included in Figure 1 for cognitively normal (A), mild cognitive impairment (B) and Alzheimer dementia (C). Curves were plotted using the point estimates generated by generalized estimating equations and are within the age limits of the diagnostic groups, adjusted for study (site) effect.
Figure S2. Prevalence of APOE ε4 in AD dementia without atypical variants
The slopes indicate that the prevalence of APOE ε4 was similar when including or excluding subjects with an atypical (non-amnestic) presentation of AD dementia. 
